NCT00962234

Brief Summary

The causes of failing nutrition status in advanced cancer are not well known. The way fat is moved, stored, burned or changed into other compounds may be affected and will be followed in patients using a tracer and other blood tests. The investigators hypothesize that fat loss and wasting results from low essential fatty acid availability in the body. Changes may occur in the liver that limits distribution and availability of fat to the body as an energy source or for other essential functions.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2009

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 17, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 19, 2009

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2009

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
Last Updated

February 26, 2016

Status Verified

April 1, 2012

Enrollment Period

2 years

First QC Date

August 17, 2009

Last Update Submit

February 24, 2016

Conditions

Keywords

LipogenesisLipolysisPhospholipidsBody CompositionNutritional StatusLipid Metabolism

Outcome Measures

Primary Outcomes (1)

  • Rate of hepatic de novo lipogenesis

    9 months

Secondary Outcomes (2)

  • Measures of fat transport and availability

    9 months

  • Resting metabolic rate & fat oxidation

    9 months

Study Arms (1)

Metabolism

Lung cancer patients who exhibit abnormalities in lipid measures.

Other: Blood drawsBiological: Oral administration of stable isotope (deuterium)Procedure: Metabolic rate testing

Interventions

Up to 4 blood draws will be required, in the amount of about 10 mL each

Metabolism

1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours

Also known as: C/D/N Isotopes, Deuterium Oxide, CAS No: 7789-20-0
Metabolism

Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.

Metabolism

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Lung cancer patients

You may qualify if:

  • Low plasma phospholipids OR low plasma ratio of triglycerides to free fatty acids
  • Recent weight loss
  • Advanced stage lung cancer (Stage 3 or 4)

You may not qualify if:

  • Having symptoms that may affect measures of fat metabolism (nausea, vomiting, problems swallowing, etc.)
  • Taking n-3 fatty acid supplements such as fish oil

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Lung NeoplasmsCachexia

Interventions

Blood Specimen CollectionDeuteriumDeuterium Oxide

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesWeight LossBody Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsThinness

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesHydrogenElementsInorganic ChemicalsGasesIsotopesWaterHydroxidesAlkaliesAnionsIonsElectrolytes

Study Officials

  • Vera Mazurak, PhD

    AHS Cancer Control Alberta

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 17, 2009

First Posted

August 19, 2009

Study Start

October 1, 2009

Primary Completion

October 1, 2011

Study Completion

October 1, 2011

Last Updated

February 26, 2016

Record last verified: 2012-04

Locations